The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
59
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
RECRUITINGTo estimate overall response rate
Overall response rate (ORR) as determined by RECIST criteria. Response will be defined by a complete response (CR) or partial response (PRO), confirmed or unconfirmed.
Time frame: 3 years
Progression-free survival
Progression-free survival (PFS) defined as the duration from the first study dose of study drug until progressive disease, death or last assessment contact whichever comes first.
Time frame: From first dose of study drug until progressive disease, death or last assessment contact, whichever comes first, an average of 1-2 years
Overall Survival
Overall Survival (OS) is defined as the time from the first dose of study drug until death due to any cause or last observation or contact.
Time frame: from the first dose of study drug until death, last observation or contact, an average of 1-2 years
Safety Evaluations: number of Grade ≥ 3 as determined by CTCAE v 5.0
Toxicity will be estimated by the number of Grade ≥ 3 as determined by CTCAE v 5.0.
Time frame: Initiation through 30 days following the last administration of study treatment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.